Zacks Investment ResearchFri, 17 Apr 2026 18:40:27 GMTCan Myqorzo Drive Growth for Cytokinetics Amid Competition?CYTK-0.97%
Zacks Investment ResearchThu, 26 Mar 2026 16:32:56 GMTWhy Is Cytokinetics (CYTK) Down 0.8% Since Last Earnings Report?CYTK-0.97%
Seeking AlphaWed, 11 Mar 2026 20:12:21 GMTCytokinetics, Incorporated (CYTK) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptCYTK-0.97%
The Motley FoolMon, 09 Mar 2026 18:18:32 GMTCytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the MarketCYTK-0.97%
Zacks Investment ResearchWed, 25 Feb 2026 19:45:32 GMTCYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch PlansCYTK-0.97%
Seeking AlphaWed, 25 Feb 2026 06:07:53 GMTCytokinetics, Incorporated (CYTK) Q4 2025 Earnings Call TranscriptCYTK-0.97%
Zacks Investment ResearchWed, 25 Feb 2026 01:31:54 GMTCytokinetics (CYTK) Reports Q4 Loss, Beats Revenue EstimatesCYTK-0.97%
Zacks Investment ResearchWed, 18 Feb 2026 15:35:21 GMTCytokinetics Wins EU Approval for Cardiovascular Drug MyqorzoCYTK-0.97%
Zacks Investment ResearchTue, 17 Feb 2026 16:01:57 GMTEarnings Preview: Cytokinetics (CYTK) Q4 Earnings Expected to DeclineCYTK-0.97%
